relation to Dose) study drug) Female, 24 None / None 2 Cycles (96 Thyroid 688 days 315 days mg) cancer (23 months) (10 (Grade 3, months) serious, related) Female, 46 Dysplastic naevus 2 Cycles (90 Basal cell (~19 (~5 syndrome, mg) carcinoma months) months) thyroid neoplasm, (Grade 3, thyroidectomy / serious, former tobacco related) use Female, 44 Basal cell 2 Cycles (96 Malignant 759 days 385 days carcinoma / None mg) melanoma in (25 months) situ (Grade 3, serious, related) Female, 50 Hypothyroidism, 1 Cycle (60 Thyroid 325 days 321 days thyroid neoplasm mg) cancer (11 months) (11 / None (Grade 3, months) serious, not related) Female, 33 Submandibular 2 Cycles (96 Thyroid 697 days 328 days node / None mg) cancer (23 months) (11 (Grade 3, months) serious, not related) Female, 33 None / None 2 Cycles (96 Thyroid 789 days 425 days mg) cancer (26 months) (14 (Grade 1, not months) serious, not related) Table 14. Listing of Malignancies in Alemtuzumab 24mg Patients Over All Available Follow Up Sex, age at Prior Medical Number of Preferred Time from Days from diagnosis History / Risk Cycles (or Term First Dose to Last Dose of Factors weeks) at (Severity Diagnosis of to malignancy Time of Grade, Malignancy Diagnosis Diagnosis of
Dose) relation to study drug) Female, 24 None / None 2 Cycles (96 mg) Thyroid cancer (Grade 3, serious, related) 688 days (23 months) 315 days (10 months) Female, 46 Dysplastic naevus syndrome, thyroid neoplasm, thyroidectomy / former tobacco use 2 Cycles (90 mg) Basal cell carcinoma (Grade 3, serious, related) (~19 months) (~5 months) Female, 44 Basal cell carcinoma / None 2 Cycles (96 mg) Malignant melanoma in situ (Grade 3, serious, related) 759 days (25 months) 385 days Female, 50 Hypothyroidism, thyroid neoplasm / None 1 Cycle (60 mg) Thyroid cancer (Grade 3, serious, not related) 325 days (11 months) 321 days (11 months) Female, 33 Submandibular node / None 2 Cycles (96 mg) Thyroid cancer (Grade 3, serious, not related) 697 days (23 months) 328 days (11 months) Female, 33 None / None 2 Cycles (96 mg) Thyroid cancer (Grade 1, not serious, not related) 789 days (26 months) 425 days (14 months) Table 14. Listing of Malignancies in Alemtuzumab 24mg Patients Over All Available Follow Up Sex, age at diagnosis of malignancy Prior Medical History / Risk Factors Number of Cycles (or weeks) at Time of Diagnosis Preferred Term (Severity Grade, Time from First Dose to Diagnosis of Malignancy Days from Last Dose to Diagnosis of